Pfizer (PFE) Set to Post Quarterly Earnings on Tuesday

Key Points

• Pfizer is scheduled to report Q3 2026 results before the market opens on November 3. Analysts expect $0.728 in earnings per share and $15.86 billion in revenue, compared with full-year guidance of $2.80–$3.00 EPS.
• The company recently delivered better-than-expected results, reporting $0.77 EPS and $15.03 billion in revenue, while its pipeline gained momentum through positive ELREXFIO trial data and expanded FDA approval for TALZENNA plus XTANDI.
• Pfizer offers a 5.8% dividend yield, but its payout ratio is elevated at 226%. Analysts broadly maintain a “Hold” view, with 14 hold ratings and an average price target of $28.72 versus the stock’s $29.80 opening price.

Pfizer (NYSE:PFE - Get Free Report) is projected to release its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of $0.7280 per share and revenue of $15.86 billion for the quarter. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Individuals may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 10:00 AM ET.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the firm earned $0.78 EPS. The business's revenue was up 2.6% on a year-over-year basis. On average, analysts expect Pfizer to post $2.94 EPS for the current fiscal year and $2.95 EPS for the next fiscal year.

Pfizer Price Performance

Shares of NYSE PFE opened at $29.80 on Tuesday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $169.82 billion, a price-to-earnings ratio of 39.20, a price-to-earnings-growth ratio of 2.04 and a beta of 0.32. Pfizer has a twelve month low of $23.62 and a twelve month high of $30.44. The business has a 50 day simple moving average of $28.30 and a 200-day simple moving average of $26.67.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.8%. Pfizer's payout ratio is presently 226.32%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PFE. HSBC increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a report on Thursday, September 10th. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a report on Saturday, October 10th. JPMorgan Chase & Co. boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday, October 9th. BMO Capital Markets dropped their price objective on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, July 13th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, October 13th. Five research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average price target of $28.72.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO in relapsed or refractory multiple myeloma met its primary progression-free-survival endpoint at an interim analysis and outperformed standard treatment regimens. The result strengthens the drug’s potential as a growth driver, though full data and regulatory steps remain ahead. Pfizer ELREXFIO Phase 3 study results
• Positive Sentiment: The FDA expanded approval for Pfizer’s TALZENNA plus XTANDI combination into an earlier treatment setting for men with metastatic hormone-sensitive prostate cancer and HRR gene mutations, including BRCA and non-BRCA mutations. The broader label increases the drugs’ addressable patient population and commercial opportunity. Pfizer TALZENNA and XTANDI FDA approval
• Neutral Sentiment: Pfizer presented Phase 2 results across serotypes for its 25-valent pneumococcal vaccine candidate, 25vPnC. The update provides additional pipeline information, but the eventual stock impact depends on detailed efficacy, safety, and regulatory outcomes. Pfizer 25vPnC Phase 2 results
• Neutral Sentiment: Pfizer appeared relatively resilient as broader healthcare stocks weakened, suggesting limited company-specific pressure from the sector’s late-session softness. Healthcare sector update
• Negative Sentiment: After a strong 2026 advance, valuation-focused coverage argues that Pfizer’s shares may be above fair value, with estimates indicating limited or negative upside from current levels. This raises the risk of profit-taking unless earnings and pipeline growth accelerate. Pfizer valuation and November 3 outlook

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.